Exploration of the benefits and resistance mechanisms of immunotherapy based on PD-L1 expression, circulating tumor DNA and T-cell receptor profiles in advanced gastric cancer
Cancer Immunology, Immunotherapy · 2025
DOI: 10.1007/s00262-025-04248-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Miaomiao Gou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Senior department of oncology, Chinese PLA General hospital, Dongda street 8, Fengtai District, Beijing, 100853, China. Hauptthemen laut MEDLINE: Stomach Neoplasms, B7-H1 Antigen, Circulating Tumor DNA, Immunotherapy. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: Combination regimens of immunotherapy and chemotherapy have become the standard treatment for HER2-negative advanced gastric cancer (AGC). Here, we evaluate the therapeutic efficacy of first-line treatment regimens across different PD-L1 expression, circulating tumor DNA (ctDNA) and T-cell receptor (TCR). METHODS: This study retrospectively recruited 245 patients with AGC. 55 blood samples from 20 patients were prospectively collected before immunotherapy, after two cycles of treatment, and during disease progression. RESULTS: In the CPS < 5 cohort, chemotherapy + PD-1 inhibitor + anti-angiogenic treatment showed a higher progression-free survival (PFS). In the CPS ≥ 5 cohort, chemotherapy + PD-1 inhibitor improved median PFS (p = 0.04) and ORR (p = 0.014) over chemotherapy alone. ctDNA analysis revealed that at various time points, patients in the short-PFS group exhibited significantly elevated maxVAF and ctDNA levels. Post-treatment, ctDNA levels decreased in 50% of patients in the long-PFS group, whereas only 25% in the short-PFS group. The short-PFS group had a lower TCR clone count, while no significantly different in the diversity of the TCR repertoire compared with long-PFS groups. CONCLUSIONS: These findings suggest the different efficacy of first-line treatment regimens across varying levels of PD-L1 expression, and the molecular characteristics of patients with long-term benefits from immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Senior department of oncology, Chinese PLA General hospital, Dongda street 8, Fengtai District, Beijing, 100853, China.
- The Eighth Medical Center, Chinese People's Liberation Army General Hospital, Beijing, China.
- Medical Oncology Department, the Second Medical Center, Chinese People's Liberation Army General Hospital, Beijing, China.
- Geneplus-Beijing Institute, Beijing, China.
- State Key Laboratory of Microbial Resources, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
- Senior department of oncology, Chinese PLA General hospital, Dongda street 8, Fengtai District, Beijing, 100853, China. daigh60@sohu.com.
Zitieren
APA
Gou, M., Qian, N., Zhang, Y., Yan, B., Wang, Z., & Dai, G. (2025). Exploration of the benefits and resistance mechanisms of immunotherapy based on PD-L1 expression, circulating tumor DNA and T-cell receptor profiles in advanced gastric cancer. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04248-0
Vancouver
Gou M, Qian N, Zhang Y, Yan B, Wang Z, Dai G. Exploration of the benefits and resistance mechanisms of immunotherapy based on PD-L1 expression, circulating tumor DNA and T-cell receptor profiles in advanced gastric cancer. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-04248-0
BibTeX
@article{Gou2025,
author = {Gou, Miaomiao and Qian, Niansong and Zhang, Yong and Yan, Bingfa and Wang, Zhikuan and Dai, Guanghai},
title = {Exploration of the benefits and resistance mechanisms of immunotherapy based on PD-L1 expression, circulating tumor DNA and T-cell receptor profiles in advanced gastric cancer},
journal = {Cancer Immunology, Immunotherapy},
year = {2025},
doi = {10.1007/s00262-025-04248-0}
}
EUVIMED